Statement from FDA Commissioner and Director of the Center for Devices and Radiological Health on new steps to promote innovations in medical devices that help advance patient safety

18 December 2018 - Spurring innovation of medical products so that patients can have access to safe, effective treatments that ...

Read more →

Antimicrobial resistance: FDA discusses reimbursement reforms

17 September 2018 - Reimbursement reforms for antimicrobial treatments could include “a mix of milestone payments and subscription fees for ...

Read more →

FDA’s comprehensive effort to advance new innovations: initiatives to modernise for innovation

29 August 2018 - Our longstanding goal for medical care is to ensure that the right drug or device is delivered ...

Read more →

FDA launches new pilot to advance innovative clinical trial designs as part of agency’s broader program to modernise drug development and promote innovation in drugs targeted to unmet needs

29 August 2018 - Today, the U.S. FDA announced a new pilot program (“Complex Innovative Designs Pilot Meeting Program”) in which ...

Read more →

Statement from FDA Commissioner on advancing the science and regulation of live microbiome-based products used to prevent, treat, or cure diseases in humans

16 August 2018 - Over the last several years, there’s been growing scientific and public interest in the role of microorganisms ...

Read more →

FDA supports critical research to spur innovation for continuous manufacturing technology to support and advance drug and biologics development

1 August 2018 - We know that novel manufacturing technologies for both small-molecule drugs and biological products have great potential to ...

Read more →

FDA’s new efforts to advance biotechnology innovation

6 June 2018 - Scientific advances in biotechnology, such as genome editing and synthetic biology, hold enormous potential to improve human ...

Read more →

Embracing competition to empower biosimilars

5 June 2018 - In 2017, there were 46 new novel drug innovations, including new treatments for cancers, Parkinson’s disease, ...

Read more →

As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion

30 May 2018 - Agency will work closely with selected applicants to accelerate product development. ...

Read more →

Breakthrough-therapy designation — an FDA perspective

12 April 2018 - Recent medical advances, such as targeted therapies for specific tumour genomic defects, checkpoint inhibitors for cancers, and ...

Read more →

Balancing safety and innovation for cell-based regenerative medicine

8 March 2018 - Regenerative medicine is a field that involves replacing, engineering, or regenerating human cells, tissues, or organs to ...

Read more →

Statement from FDA Commissioner Scott Gottlieb on Administration’s request for new FDA funding to promote innovation and broaden patient access through competition

13 February 2018 - Additional resources will help advance initiatives to support novel medical technology and public health priorities such as ...

Read more →

Reflections on a landmark year for medical product innovation and public health advances and looking ahead to policy in 2018

9 January 2018 - As we look ahead to 2018, I’d like to take a moment to reflect on an ...

Read more →

New steps to facilitate beneficial medical device innovation

14 December 2017 - In recent days, the FDA has committed to several new policies that will modernise the agency’s approach ...

Read more →

Bumper crop of new drugs fails to lift big pharma R&D returns

14 December 2017 - It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice ...

Read more →